John Barker Harley, 742333 Raeburn Ter, Cincinnati, OH 45223

6641813, Nov 4, 2003

Jun 7, 1995

08/475955

John B. Harley - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 3900

4241851, 514 13, 514 14, 514 15, 514 16, 530326, 530327, 530328

A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/Bâ polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patients. These peptides are useful in solid phase assays for patients characterized by the presence of these autoantibodies, and can be used to categorize patients as to the likelihood of developing certain conditions associated with SLE. The peptides are also potentially useful in treatment of these patients using immobilized peptide to remove autoantibody and to block binding of the autoantibodies with patient molecules reactive with the autoantibodies.

6642008, Nov 4, 2003

Nov 22, 2000

09/718693

John B. Harley - Oklahoma City OK
Judith Ann James - Edmond OK
Kenneth M. Kaufman - Oklahoma City OK

Oklahoma Medical Research Foundation - Oklahoma City OK

G01N 3353

435 71, 435 6, 435 794

Compositions that bind specific viral proteins expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP- A, an EBV latent protein, conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for infected cell removal. These antibodies can distinguish cells expressing EBV DNA from cells which do not. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also discloset. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people harboring latent viral particles.

6897287, May 24, 2005

Apr 13, 1992

07/867819

John B. Harley - Oklahoma City OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K038/04

530327, 530326, 530328, 435 71

A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B′ polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patients. These peptides are useful in solid phase assays for patients characterized by the presence of these autoantibodies, and can be used to categorize patients as to the likelihood of developing certain conditions associated with SLE. The peptides are also potentially useful in treatment of these patients using immobilized peptide to remove autoantibody and to block binding of the autoantibodies with patient molecules reactive with the autoantibodies.

7078173, Jul 18, 2006

Aug 22, 2003

10/646132

John B. Harley - Oklahoma City OK, US
Judith A. James - Edmond OK, US
Kenneth M. Kaufman - Oklahoma City OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

C12Q 1/70

435 6, 435 691, 435 71, 4352351

Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.

7192715, Mar 20, 2007

Oct 24, 2001

10/012756

John B. Harley - Oklahoma City OK, US
Judith A. James - Oklahoma City OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

G01N 33/53
A61K 38/04
A61K 38/16
A61K 38/245

435 71, 4242301, 4241851, 4241861, 530328, 530325

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity.

7273613, Sep 25, 2007

Feb 9, 2000

09/500904

John B. Harley - Oklahoma City OK, US
Judith A. James - Edmond OK, US
Kenneth M. Kaufman - Oklahoma City OK, US

The Board of Regents, The University of Oklahoma - Norman OK
Oklahoma Medical Research Foundation - Oklahoma City OK

C07K 5/00
A61K 39/00
C12Q 1/70

4241861, 435975, 435 71, 530300, 530324, 530327, 530326

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity.

7276341, Oct 2, 2007

Feb 27, 2003

10/376121

John B. Harley - Oklahoma City OK, US
Judith A. James - Edmond OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

G01N 33/53
G01N 33/00
A61K 38/04
C07K 5/00
C07K 7/00
C07K 16/00
C07K 17/00

435 71, 435 792, 530326, 530327, 530328, 530329

A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B′ polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patients. These peptides are useful in solid phase assays for patients characterized by the presence of these autoantibodies, and can be used to categorize patients as to the likelihood of developing certain conditions associated with SLE. The peptides are also potentially useful in treatment of these patients using immobilized peptide to remove autoantibody and to block binding of the autoantibodies with patient molecules reactive with the autoantibodies.

7410642, Aug 12, 2008

Apr 17, 2006

11/405355

John B. Harley - Oklahoma City OK, US
Judith Ann James - Edmond OK, US
Kenneth M. Kaufman - Oklahoma City OK, US

Oklahoma Medical Research Foundation - Oklahoma City OK

A61K 39/12

4242041, 4241301, 435345

Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.